Effect of aclidinium bromide on cough and sputum symptoms in moderate-to-severe COPD in three Phase III trials

This analysis examined cough-related symptoms across three Phase III trials of aclidinium bromide in patients with stable COPD. Endpoints of interest included change in E-RS score, total and cough/sputum scores, and frequency/severity of morning and night-time cough and sputum symptoms.